Skip to main content
. 2019 Jan 3;16(1):91–98. doi: 10.21873/cgp.20115

Table II. Diagnosis of patients in this study according to mutation status.

graphic file with name cgp-16-94-i0001.jpg

SF3B1: Splicing factor 3B subunit 1; TET2: tet methylcytosine dioxygenase 2. AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm. Other: One patient with therapy-related myeloid neoplasm, four with aplastic anemia, and 12 with bone marrow with no obvious morphological abnormalities. abSignificantly different from TET2.